Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proellex Vaginal for Uterine Fibroids
NCT02323646Phase 2Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Feb 2015
- Primary completion
- Apr 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of telapristone in Uterine Fibroids (UF) (3 arms), sponsored by Repros Therapeutics Inc. Primary endpoint: Percentage of Participants in Amenorrhea at the End of Treatment Course 1 at 18 weeks. Started Feb 2015; status: completed.
02
Drugs
telapristone
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT02323646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323646.